MedTrace Logo

Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination

NCT05859490 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-07-31

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are:

* how does prior vaccination affect antibody responses to re-vaccination?
* how does prior vaccination affect the immune cell response to re-vaccination?

Participants will:

* have been previously vaccinated with 17D.
* be re-vaccinated with 17D.
* provide medical and travel histories.
* provide a blood sample prior to vaccination
* provide a blood sample approximately every other day for 14 days after vaccination.
* provide a blood sample approximately 28 days after vaccination.
* complete a daily diary of symptoms following vaccination for 14 days.
* report any additional symptoms after 14 days.

Conditions

  • Yellow Fever
  • Immunization; Infection

Interventions

BIOLOGICAL

17D

Vaccine administration in subjects previously vaccinated with 17D.

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • William Messer, MD PhD · Oregon Health and Science University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-11-01
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859490 on ClinicalTrials.gov